Literature DB >> 19959353

Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline.

Claus Garbe1, Ketty Peris, Axel Hauschild, Philippe Saiag, Mark Middleton, Alain Spatz, Jean-Jacques Grob, Josep Malvehy, Julia Newton-Bishop, Alexander Stratigos, Hubert Pehamberger, Alexander Eggermont.   

Abstract

Cutaneous melanoma (CM) is potentially the most dangerous form of skin tumour and causes 90% of skin cancer mortality. A unique collaboration of multi-disciplinary experts from the European Dermatology Forum, the European Association of Dermato-Oncology and the European Organization of Research and Treatment of Cancer was formed to make recommendations on CM diagnosis and treatment, based on systematic literature reviews and the experts' experience. Diagnosis is made clinically and staging is based upon the AJCC system. CMs are excised with one to two centimetre safety margins. Sentinel lymph node dissection is routinely offered as a staging procedure in patients with tumours more than 1mm in thickness, although there is as yet no resultant survival benefit. Interferon-alpha treatment can be offered to patients with more than 1.5mm in thickness and stage II to III melanoma as an adjuvant therapy, as this treatment increases the relapse-free survival. The lack of a clear survival benefit and the presence of toxicity however limit its use in practice. In distant metastasis, all options of surgical therapy have to be considered thoroughly. In the absence of surgical options, systemic medical treatment is indicated, but with, to date, low response rates. Therapeutic decisions should be made by the melanoma team and the informed patient after full discussion of the options. Copyright 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19959353     DOI: 10.1016/j.ejca.2009.10.032

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  49 in total

1.  The FGF-2-derived peptide FREG inhibits melanoma growth in vitro and in vivo.

Authors:  Maria S Aguzzi; Debora Faraone; Daniela D'Arcangelo; Francesco De Marchis; Gabriele Toietta; Domenico Ribatti; Alberto Parazzoli; Paolo Colombo; Maurizio C Capogrossi; Antonio Facchiano
Journal:  Mol Ther       Date:  2010-10-05       Impact factor: 11.454

2.  Addison's disease as a presentation of metastatic malignant melanoma.

Authors:  B Srinivasan; M Patel; M Ethunandan; V Ilankovan
Journal:  Ann R Coll Surg Engl       Date:  2016-01       Impact factor: 1.891

Review 3.  New vitamin D analogs as potential therapeutics in melanoma.

Authors:  Paulina Szyszka; Michal A Zmijewski; Andrzej T Slominski
Journal:  Expert Rev Anticancer Ther       Date:  2012-05       Impact factor: 4.512

4.  Correlation of histological and ex-vivo confocal tumor thickness in malignant melanoma.

Authors:  Daniela Hartmann; Sebastian Krammer; Cristel Ruini; Thomas Ruzicka; Tanja von Braunmühl
Journal:  Lasers Med Sci       Date:  2016-04-07       Impact factor: 3.161

5.  A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.

Authors:  Lawrence Flaherty; Omid Hamid; Gerald Linette; Lynn Schuchter; Sigrun Hallmeyer; Rene Gonzalez; C Lance Cowey; Anna Pavlick; Fred Kudrik; Brendan Curti; David Lawson; Paul B Chapman; Kim Margolin; Antoni Ribas; David McDermott; Keith Flaherty; Lee Cranmer; F Stephen Hodi; Bann-Mo Day; Rolf Linke; John Hainsworth
Journal:  Cancer J       Date:  2014 Jan-Feb       Impact factor: 3.360

6.  Evaluation of multiple serum markers in advanced melanoma.

Authors:  Angel Díaz-Lagares; Estíbaliz Alegre; Ainhoa Arroyo; María González-Cao; Maria E Zudaire; Santiago Viteri; Salvador Martín-Algarra; Alvaro González
Journal:  Tumour Biol       Date:  2011-08-20

7.  Can integrated 18F-FDG PET/MR replace sentinel lymph node resection in malignant melanoma?

Authors:  Benedikt Michael Schaarschmidt; Johannes Grueneisen; Vanessa Stebner; Joachim Klode; Ingo Stoffels; Lale Umutlu; Dirk Schadendorf; Philipp Heusch; Gerald Antoch; Thorsten Dirk Pöppel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-06-06       Impact factor: 9.236

Review 8.  Tissue prognostic biomarkers in primary cutaneous melanoma.

Authors:  Mario Mandalà; Daniela Massi
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

Review 9.  [Immunotherapy of melanomas].

Authors:  L Zimmer; J Vaubel; D Schadendorf
Journal:  Hautarzt       Date:  2012-12       Impact factor: 0.751

10.  Photosensitizing and radiosensitizing effects of mitoxantrone: combined chemo-, photo-, and radiotherapy of DFW human melanoma cells.

Authors:  Ameneh Sazgarnia; Ali Reza Montazerabadi; Mohammad Hossein Bahreyni-Toosi; Amirhossein Ahmadi
Journal:  Lasers Med Sci       Date:  2013-02-01       Impact factor: 3.161

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.